News & events

Press Releases

On the 28th March 2022, OncoArendi changed its name to Molecure

Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

29 March 2024

Invitation to investor meeting 10th April 2024, 2:00 pm (CET)

28 March 2024

First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis

22 March 2024

Molecure has submitted a new application for approval to conduct a Phase II clinical trial for clinical candidate OATD-01 in the countries of the European Union and Norway

9 February 2024

Molecure invites to the R&D Day – an online scientific and educational meeting on February 6, 2024

29 January 2024

Molecure’s success in development of the mRNA discovery platform

12 December 2023

Events & Presentations

R&D Day Presentation, 07.12.2022

7 December 2022

Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada

27 February 2020

EFMC-ASMC’19 – September 1-5, 2019 | Athens, Greece

11 September 2019

ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA

4 September 2019

ATS- International Conference – Dallas, 17-22.05.2019

22 May 2019

EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018

17 September 2018
This site is registered on wpml.org as a development site.